Association of amino acid sequence in the PKR-eIF2 phosphorylation homology domain and response to interferon therapy

Hepatology

Volumn 32, Issue 5, 2000, Pages 1138-1144

  Chayama, Kazuaki ^a   Suzuki, Fumitaka ^a   Tsubota, Akihito ^a   Kobayashi, Masahiro ^a   Arase, Yasuji ^a   Saitoh, Satoshi ^a   Suzuki, Yoshiyuki ^a   Murashima, Naoya ^a   Ikeda, Kenji ^a   Takahashi, Norihiko ^b   Kinoshita, Moritoshi ^b   Kumada, Hiromitsu ^a  

^a TORANOMON HOSPITAL   (Japan)

^b OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; PROTEIN KINASE; VIRUS ENZYME;

ADULT; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME PHOSPHORYLATION; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN DOMAIN; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

EID: 0033754631     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2000.19364     Document Type: Article

References (39)

1. Prognosis of chronic hepatitis C: Results of a large, prospective cohort study
2. The natural course of chronic hepatitis C: Implications for clinical practice
3. Disease progression and hepatocellular carcinogenesis in patients with chronic viral hepatitis: A prospective observation of 2215 patients
4. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group
5. Treatment of chronic hepatitis C with recombinant interferon alfa
6. Recombinant interferon alfa therapy for chronic hepatitis C
7. Effect of interferon administration on serum hepatitis C virus RNA in patients with chronic hepatitis C
8. Long-term follow-up of patients with chronic hepatitis C treated with interferon
9. Prediction of response to interferon treatment of chronic hepatitis C
10. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection
11. Detection of hepatitis C virus by polymerase chain reaction and response to interferon-alpha therapy: Relationship to genotypes of hepatitis C virus
12. Comparison of full-length sequences of interferonsensitive and resistant hepatitis C virus 1b
13. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection
14. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein: Molecular mechanisms of kinase regulation
15. Protein, nucleotide evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein
16. Pretreatment virus load and multiple amino acid substitutions in the interferon sensitivity-determining region predict the outcome of interferon treatment in patients with chronic genotype 1b hepatitis C virus infection
17. Mutations in the NS5A gene predict response to interferon therapy in Japanese patients with chronic hepatitis C and cirrhosis
18. Why is the interferon sensitivity-determining region (ISDR) system useful in Japan?
19. Differential effect of interferon on hepatitis C virus 1b quasispecies in the nonstructural protein 5A gene
20. The NS5a gene of hepatitis C virus in patients treated with interferon-alpha
21. Hepatitis C virus NS5A protein inhibits interferon antiviral activity, but the effects do not correlate with clinical response
22. Long-term response to interferon alpha is unrelated to 'interferon sensitivity determining region' variability in patients with chronic hepatitis C virus-1b infection
23. The NS5a gene of hepatitis C virus in patients treated with interferon-alpha
24. Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype la or 1b
25. Mutations of hepatitis C virus 1b NS5A 2209-2248 amino acid sequence do not predict the response to recombinant interferon-alfa therapy in French patients
26. Mutations in the NS5A region do not predict interferon-responsiveness in American patients infected with genotype 1b hepatitis C virus
27. Mutations in the nonstructural 5A region of hepatitis C virus and response of chronic hepatitis C to interferon alfa
28. Mutations in the nonstructural 5A gene of European hepatitis C virus isolates and response to interferon alfa
29. Improved correlation between multiple mutations within the NS5A region and virological response in European patients chronically infected with hepatitis C virus type 1b undergoing combination therapy
30. Evidence for sequence selection within the non-structural 5A gene of hepatitis C virus type 1b during unsuccessful treatment with interferon-alpha
31. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein
32. Genotypic subtyping of hepatitis C virus
33. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology
34. Real-time detection system for quantification of hepatitis C virus genome
35. Quantitation of hepatitis C viral RNA in liver and serum samples using competitive polymerase chain reaction
36. Serum levels of hepatitis C virus core protein in patients with chronic hepatitis C treated with interferon alfa
37. Avoiding false positives with PCR
38. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis